Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.

In a report released today, Kaveri Pohlman from Clear Street reiterated a Buy rating on Immatics, with a price target of $18.00. Pohlman covers the...

Clear Street Reaffirms Their Buy Rating on Immatics (IMTX)

Immatics ( ($IMTX) ) just unveiled an announcement. On December 8, 2025, Immatics N.V. completed an offering of 12,500,000 ordinary shares, raising...

Immatics Completes $116.5 Million Share Offering to Boost R&D

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immatics (IMTX – Research Report), Incyte (INCY – Research Report...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Cogent Biosciences (COGT)

Immatics N.V. ( ($IMTX) ) has released its Q3 earnings. Here is a breakdown of the information Immatics N.V. presented to its investors. Immatics N...

Immatics N.V. Reports Q3 2025 Financial Results and Progress

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Immatics today and set a price target of $23.00. Suvannavejh covers the Heal...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMTX	$10.04	0.00%	238.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMTX	$10.04	0%	238.48K
3
4
5
6

IMTX

IMTX

Get Immatics N.V. Data in Excel

Get Immatics N.V. Data in Excel